The investigation centers on the transparency of Liquidia’s disclosures regarding its ongoing patent battle. Following the ruling on the '327 patent, Liquidia faces a potential injunction against its flagship product, Yutrepia, which generated $300.3 million in sales during the first half of 2026. Despite CEO Roger Jeffs expressing disagreement with the verdict and promising to pursue an appeal, the financial impact on shareholders remains severe.

Legal representatives are currently evaluating whether Liquidia failed to properly inform the market of the litigation's potential consequences. Investors who purchased stock at prices that may have been inflated by incomplete disclosures are being encouraged to review their eligibility for potential recovery. The firm is examining whether the company’s public filings, including its August 12, 2026, Form 10-Q, obscured the true extent of the vulnerability posed by the United Therapeutics dispute.